1-20 of 23
Nicola J. Curtin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 4125: Investigating determinants of sensitivity to ATR inhibition, as predictive biomarkers to single agent ATR inhibitor, VE-821, in ovarian cancer

Alice Mary Bradbury, Frank T. Zenke, Yvette Drew, Nicola J. Curtin
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 4125.
https://doi.org/10.1158/1538-7445.AM2020-4125
Published: 15 August 2020
View article titled, Abstract 4125: Investigating determinants of sensitivity to ATR inhibition, as predictive biomarkers to single agent ATR inhibitor, VE-821, in ovarian cancer
Journal Articles

Abstract 1375: Investigating synergy between CHK1 and PARP inhibitors in BRCA2 mutant and restored cells

Hannah L. Smith, Lisa Prendergast, Nicola J. Curtin
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 1375.
https://doi.org/10.1158/1538-7445.AM2020-1375
Published: 15 August 2020
View article titled, Abstract 1375: Investigating synergy between CHK1 and PARP inhibitors in <em>BRCA2</em> mutant and restored cells
Journal Articles

Abstract 1374: Preclinical investigation of ATR inhibition alone and in combination with PARP inhibition in high risk neuroblastoma

Harriet E. Southgate, Lindi Chen, Nicola J. Curtin, Deborah A. Tweddle
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 1374.
https://doi.org/10.1158/1538-7445.AM2020-1374
Published: 15 August 2020
View article titled, Abstract 1374: Preclinical investigation of ATR inhibition alone and in combination with PARP inhibition in high risk neuroblastoma
Journal Articles

Abstract 2448: Towards structure-based drug design of 3-phosphoglycerate dehydrogenase inhibitors

Judith E. Unterlass, Nabila Aljufri, Sophie Bex, Celine Cano, Martin E M Noble, Nicola J. Curtin
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 2448.
https://doi.org/10.1158/1538-7445.AM2015-2448
Published: 01 August 2015
View article titled, Abstract 2448: Towards structure-based drug design of 3-phosphoglycerate dehydrogenase inhibitors
Journal Articles

Abstract 1785: Chemical inhibition or transient knockdown of wild-type p53 induced phosphatase 1 (WIP1/PPM1D) potentiates the response to MDM2 inhibitors in a p53-dependent manner

Arman Esfandiari, Nicola J. Curtin, John Lunec
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 1785.
https://doi.org/10.1158/1538-7445.AM2015-1785
Published: 01 August 2015
View article titled, Abstract 1785: Chemical inhibition or transient knockdown of wild-type p53 induced phosphatase 1 (WIP1/PPM1D) potentiates the response to MDM2 inhibitors in a p53-dependent manner
Journal Articles

Abstract 2418: Investigating p53 and other potential determinants of cell sensitivity to ATR inhibition by VE-821

Fiona K. Middleton, Tao Chen, John R. Pollard, Nicola J. Curtin
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 2418.
https://doi.org/10.1158/1538-7445.AM2014-2418
Published: 01 October 2014
View article titled, Abstract 2418: Investigating p53 and other potential determinants of cell sensitivity to ATR inhibition by VE-821
Journal Articles

Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival

Asima Mukhopadhyay, Elizabeth R. Plummer, Ahmed Elattar, San Soohoo, Bisha Uzir, Jennifer E. Quinn, W. Glenn McCluggage, Perry Maxwell, Harriet Aneke, Nicola J. Curtin, Richard J. Edmondson
Journal: Cancer Research
Cancer Res (2012) 72 (22): 5675–5682.
https://doi.org/10.1158/0008-5472.CAN-12-0324
Published: 14 November 2012
View article titled, Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival
Open the PDF for Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival in another window
Includes: Supplementary data
Journal Articles

Abstract 3122: The DNA-PK inhibitor NU7441 inhibits non-homologous end joining, enhances radio- and chemosensitivity and increases dependence on homologous recombination in hepatocellular carcinoma cell lines

Liam Cornell, Joanne M. Munck, Helen L. Reeves, Nicola J. Curtin
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 3122.
https://doi.org/10.1158/1538-7445.AM2012-3122
Published: 15 April 2012
View article titled, Abstract 3122: The DNA-PK inhibitor NU7441 inhibits non-homologous end joining, enhances radio- and chemosensitivity and increases dependence on homologous recombination in hepatocellular carcinoma cell lines
Journal Articles

Abstract 2979: Combined cdk1 and PARP inhibition results in tumor regression in a KrasG12D p53L/L murine lung adenocarcinoma model

Neil Johnson, Yu-Chen Li, Zandra Walton, Danan Li, Lisa Moreau, Scott J. Rodig, Alan D. D'Andrea, Huw Thomas, David R. Newell, Nicola J. Curtin, Kwok K. Wong, Geoffrey I. Shapiro
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 2979.
https://doi.org/10.1158/1538-7445.AM2011-2979
Published: 15 April 2011
View article titled, Abstract 2979: Combined cdk1 and PARP inhibition results in tumor regression in a KrasG12D p53L/L murine lung adenocarcinoma model
Journal Articles

Abstract 2548: Chemosensitization of cancer cells by KU-0060648: A dual inhibitor of DNA-PK and PI-3K

Michael A. Batey, Joanne M. Munck, Yan Zhao, Celine Cano, Michele Tavecchio, Julia Bardos, Roger J. Griffin, Helen Jenkins, Keith Menear, Graeme Smith, Pia Thommes, David R. Newell, Niall Martin, Nicola J. Curtin
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 2548.
https://doi.org/10.1158/1538-7445.AM2011-2548
Published: 15 April 2011
View article titled, Abstract 2548: Chemosensitization of cancer cells by KU-0060648: A dual inhibitor of DNA-PK and PI-3K
Journal Articles

6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance

Natalia Issaeva, Huw D. Thomas, Tatjana Djurenovic, Janneke E. Jaspers, Ivaylo Stoimenov, Suzanne Kyle, Nicholas Pedley, Ponnari Gottipati, Rafal Zur, Kate Sleeth, Vicky Chatzakos, Evan A. Mulligan, Cecilia Lundin, Evgenia Gubanova, Ariena Kersbergen, Adrian L. Harris, Ricky A. Sharma, Sven Rottenberg, Nicola J. Curtin, Thomas Helleday
Journal: Cancer Research
Cancer Res (2010) 70 (15): 6268–6276.
https://doi.org/10.1158/0008-5472.CAN-09-3416
Published: 28 July 2010
View article titled, 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
Open the PDF for 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance in another window
Includes: Supplementary data
Journal Articles

Abstract 3882: Compromised Cdk1 activity sensitizes BRCA-proficient cancer cells to inhibition of Poly(ADP-ribose) polymerase

Neil Johnson, Yu-Chen Li, Lisa A. Moreau, Huw D. Thomas, David R. Newell, Alan D. D'andrea, Nicola J. Curtin, Geoffrey I. Shapiro
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 3882.
https://doi.org/10.1158/1538-7445.AM10-3882
Published: 15 April 2010
View article titled, Abstract 3882: Compromised Cdk1 activity sensitizes BRCA-proficient cancer cells to inhibition of Poly(ADP-ribose) polymerase
Journal Articles

Preclinical Evaluation of a Potent Novel DNA-Dependent Protein Kinase Inhibitor NU7441

Yan Zhao, Huw D. Thomas, Michael A. Batey, Ian G. Cowell, Caroline J. Richardson, Roger J. Griffin, A. Hilary Calvert, David R. Newell, Graeme C.M. Smith, Nicola J. Curtin
Journal: Cancer Research
Cancer Res (2006) 66 (10): 5354–5362.
https://doi.org/10.1158/0008-5472.CAN-05-4275
Published: 16 May 2006
View article titled, Preclinical Evaluation of a Potent Novel DNA-Dependent Protein Kinase Inhibitor NU7441
Open the PDF for Preclinical Evaluation of a Potent Novel DNA-Dependent Protein Kinase Inhibitor NU7441 in another window
Journal Articles

Chemo-sensitization by the novel ATM inhibitor (KU-55933) is p53 independent

Yan Zhao, Yuan Lu, David R. Newell, Mark O‘connor*, Alan Lau*, Nicola Harris, Graeme C M Smith, Nicola J. Curtin
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 486.
Published: 15 April 2006
View article titled, Chemo-sensitization by the novel ATM inhibitor (KU-55933) is p53 independent
Journal Articles

Comparative activity of the potent selective CDK2 inhibitor NU6102 in CDK2 wild-type and knock-out mouse embryo fibroblasts

Yuzhu Cheng, Lan-Zhan Wang, Nicola J. Curtin, David R. Newell
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 1043–1044.
Published: 01 May 2005
View article titled, Comparative activity of the potent selective CDK2 inhibitor NU6102 in CDK2 wild-type and knock-out mouse embryo fibroblasts
Journal Articles

The effect of a novel CDK inhibitor NU2058 on antiestrogen sensitive and resistant breast cancer cell growth and downstream events

Neil Johnson, Nicola J. Curtin
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 1046.
Published: 01 May 2005
View article titled, The effect of a novel CDK inhibitor NU2058 on antiestrogen sensitive and resistant breast cancer cell growth and downstream events
Journal Articles

Radio and chemosensitization by a novel DNA-PK inhibitor (NU7441) in colon cancer

Yan Zhao, Michael Batey, Huw Thomas, Graeme C. Smith, David R. Newell, Nicola J. Curtin
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 1180–1181.
Published: 01 May 2005
View article titled, Radio and chemosensitization by a novel DNA-PK inhibitor (NU7441) in colon cancer
Journal Articles

Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM

Ian Hickson, Yan Zhao, Caroline J. Richardson, Sharon J. Green, Niall M. B. Martin, Alisdair I. Orr, Philip M. Reaper, Stephen P. Jackson, Nicola J. Curtin, Graeme C. M. Smith
Journal: Cancer Research
Cancer Res (2004) 64 (24): 9152–9159.
https://doi.org/10.1158/0008-5472.CAN-04-2727
Published: 16 December 2004
View article titled, Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM
Open the PDF for Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM in another window
Journal Articles

The use of novel CDK inhibitors in the treatment of hormone refractory breast cancer

Neil Johnson, Nicola J. Curtin
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 190.
Published: 01 April 2004
View article titled, The use of novel CDK inhibitors in the treatment of hormone refractory breast cancer
Journal Articles

Identification of the potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor NU7441 by screening of chromenone libraries

Roger J. Griffin, Nicola J. Curtin, Bernard T. Golding, Sophie Guiard, Ian R. Hardcastle, Justin J. Leahy, Caroline Richardson, Laurent Rigoreau, Graeme C. Smith
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 1236–1237.
Published: 01 April 2004
View article titled, Identification of the potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor NU7441 by screening of chromenone libraries